Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials
ObjectiveTo understand the current status of research and development (R&D) of psychotropic drugs.MethodsRetrieved psychotropic drugs clinical trials (PDCTs) registered in China from 2019 to 2024 using the platform of chinadrugtrials.org.cn, and systematically analyzed the data.ResultsInclud...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1599038/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318797475840000 |
|---|---|
| author | Chen Xu Yang Zhao Xueqin Yang Juan Zheng Qian Tang |
| author_facet | Chen Xu Yang Zhao Xueqin Yang Juan Zheng Qian Tang |
| author_sort | Chen Xu |
| collection | DOAJ |
| description | ObjectiveTo understand the current status of research and development (R&D) of psychotropic drugs.MethodsRetrieved psychotropic drugs clinical trials (PDCTs) registered in China from 2019 to 2024 using the platform of chinadrugtrials.org.cn, and systematically analyzed the data.ResultsIncluded four perspectives: 1) for general information, we screened 1377 PDCTs, with phase bioequivalency (BE) accounting for the majority (78.5%), covering 411 pharmaceutical companies and 212 leading institutions, and the start-up time in 2024 was significantly shortened (P < 0.05); 2) for indications, 11 indications were involved, with the highest number of PDCTs for depression (30.9%); 3) for drugs, 222 drugs were involved, of which 52 were innovative drugs (33 with disclosed targets), and 13 were improved new drugs with six administration routes; 4) for trial design, four exploratory designs were retrieved, including population pharmacokinetics (9), pharmacogenomics (12), biomarker detection (3), and drug combination (3).ConclusionsIn recent years, clinical trials of psychotropic drugs in China have been developing. Innovative targets discovery, dosage forms/drug delivery systems optimization, and exploratory designs have the potential to break the current treatment dilemma. This study introduced the hotspots and potential development directions of psychotropic drugs R&D in China from the above aspects, providing new ideas for psychiatric treatment, drug development, and clinical trial methods. |
| format | Article |
| id | doaj-art-89d5d07c54684e9dbb2d282dcf40f218 |
| institution | Kabale University |
| issn | 1664-0640 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj-art-89d5d07c54684e9dbb2d282dcf40f2182025-08-20T03:50:44ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402025-07-011610.3389/fpsyt.2025.15990381599038Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trialsChen XuYang ZhaoXueqin YangJuan ZhengQian TangObjectiveTo understand the current status of research and development (R&D) of psychotropic drugs.MethodsRetrieved psychotropic drugs clinical trials (PDCTs) registered in China from 2019 to 2024 using the platform of chinadrugtrials.org.cn, and systematically analyzed the data.ResultsIncluded four perspectives: 1) for general information, we screened 1377 PDCTs, with phase bioequivalency (BE) accounting for the majority (78.5%), covering 411 pharmaceutical companies and 212 leading institutions, and the start-up time in 2024 was significantly shortened (P < 0.05); 2) for indications, 11 indications were involved, with the highest number of PDCTs for depression (30.9%); 3) for drugs, 222 drugs were involved, of which 52 were innovative drugs (33 with disclosed targets), and 13 were improved new drugs with six administration routes; 4) for trial design, four exploratory designs were retrieved, including population pharmacokinetics (9), pharmacogenomics (12), biomarker detection (3), and drug combination (3).ConclusionsIn recent years, clinical trials of psychotropic drugs in China have been developing. Innovative targets discovery, dosage forms/drug delivery systems optimization, and exploratory designs have the potential to break the current treatment dilemma. This study introduced the hotspots and potential development directions of psychotropic drugs R&D in China from the above aspects, providing new ideas for psychiatric treatment, drug development, and clinical trial methods.https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1599038/fullpsychiatric disorderspharmacotherapyclinical trialsinnovative drugsdrug optimizationtrial design |
| spellingShingle | Chen Xu Yang Zhao Xueqin Yang Juan Zheng Qian Tang Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials Frontiers in Psychiatry psychiatric disorders pharmacotherapy clinical trials innovative drugs drug optimization trial design |
| title | Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials |
| title_full | Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials |
| title_fullStr | Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials |
| title_full_unstemmed | Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials |
| title_short | Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials |
| title_sort | exploration of current situation of psychotropic drugs research and development in china based on drug clinical trials |
| topic | psychiatric disorders pharmacotherapy clinical trials innovative drugs drug optimization trial design |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1599038/full |
| work_keys_str_mv | AT chenxu explorationofcurrentsituationofpsychotropicdrugsresearchanddevelopmentinchinabasedondrugclinicaltrials AT yangzhao explorationofcurrentsituationofpsychotropicdrugsresearchanddevelopmentinchinabasedondrugclinicaltrials AT xueqinyang explorationofcurrentsituationofpsychotropicdrugsresearchanddevelopmentinchinabasedondrugclinicaltrials AT juanzheng explorationofcurrentsituationofpsychotropicdrugsresearchanddevelopmentinchinabasedondrugclinicaltrials AT qiantang explorationofcurrentsituationofpsychotropicdrugsresearchanddevelopmentinchinabasedondrugclinicaltrials |